Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sundia MediTech Rides WuXi IPO to Series B Funding

publication date: Jan 18, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Sundia MediTech Company, a Shanghai-based CRO, has completed its second round of capital funding, though the amount raised was not disclosed. Sundia said that the fund raising has been underway since last summer, about the time that WuXi PharmaTech made its IPO on the NYSE. Company officials said that the success of the WuXi offering helped Sundia in its efforts. It also didn’t hurt that, last summer, Sundia was also ranked as number 16 on the Venture 50 list, a ranking of the most promising investment opportunities in China put together by investment house Zero2IPO. More details...

Stock Symbol: (NYSE: WX) 




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors